History

BPC-157 traces to Predrag Sikiric, a Croatian researcher at the University of Zagreb, who pursued the idea from the 1970s and reported isolating the peptide around 1989 from gastric juice. His group published on it in the early 1990s and patented related compounds. Whether the sequence truly occurs naturally in humans remains disputed, and there is little published human clinical data — most evidence comes from rodent and cell studies. It remains unapproved and gray-market, though regulators are weighing its compounding status.

BPC-157 is one of the most hyped “healing peptides” in the recovery and longevity world. Strip away the marketing, and the human evidence is remarkably thin.

What it is

BPC-157 (sometimes written “stable gastric pentadecapeptide BPC 157”) is a synthetic chain of 15 amino acids. Its sequence corresponds to a fragment of a protein found in human gastric juice, but the compound itself is lab-made and is not known to occur naturally in this form. It is sold mostly as an injectable or oral “research chemical” through gray-market vendors. It is not a dietary supplement and not an approved drug.

The claims

Marketing pitches BPC-157 as an all-purpose repair agent: faster healing of tendons, ligaments, muscle, and bone; gut healing (including inflammatory bowel disease); reduced inflammation; and even neuroprotective and mood benefits. The proposed mechanism centers on promoting angiogenesis (the growth of new blood vessels) and modulating nitric oxide signaling.

What the evidence actually shows

Almost all of the supporting research is in rats and other animals, or in cell cultures. That body of work is genuinely large and often positive, reporting accelerated tissue healing and few obvious short-term harms in rodents. A notable caveat: a large share of it traces back to a single research group (the lab of Predrag Sikirić in Croatia), and independent replication is thin.

Human evidence is another matter. There are no published, peer-reviewed randomized controlled trials. The handful of human reports that exist are tiny (roughly 2 to 16 participants each, well under 30 people total across all published studies), have no comparison groups, and come from a single group of clinicians. A Phase 1 trial of BPC-157 registered in 2015 was cancelled in 2016 without published results. Older Croatian (PLIVA) work on a related formulation (PL 14736) for ulcerative colitis — including a randomized, placebo-controlled enema study — was presented at conferences but does not appear as a peer-reviewed publication in major databases, so its results cannot be independently checked. In short, impressive animal data has not been confirmed in well-designed human studies, and basic human pharmacokinetics (how it is absorbed, dosed, and cleared) remain largely uncharacterized.

A few tiny, uncontrolled pilot reports are not enough to call this “preliminary human” evidence in any meaningful sense: with no controls, no replication, and a single source, they cannot establish whether BPC-157 actually works in people. The honest grade rests on the animal literature.

Legal and regulatory status

A few separate facts often get blurred together, so take them one at a time.

BPC-157 is not approved by the FDA for any use. In 2023 the FDA placed it on its Category 2 list of “bulk drug substances that may present significant safety risks,” effectively telling compounding pharmacies not to make it, citing concerns about immunogenicity, peptide-related impurities, and limited human safety data.

The picture shifted in 2026. In April 2026 the FDA removed BPC-157 (along with 11 other peptides, 12 in total) from that Category 2 list and scheduled a Pharmacy Compounding Advisory Committee review for July 23–24, 2026. Importantly, removal from Category 2 does not mean approval and does not by itself make it legal to compound. As of June 2026 it sits in a gray zone: no longer formally flagged as a safety-risk substance, but not added to the 503A bulks list that would permit compounding, and not an approved drug.

It also remains banned in sport. The U.S. Anti-Doping Agency and WADA prohibit BPC-157 at all times under category S0 (non-approved substances), with no path to a therapeutic use exemption. Athletes have been sanctioned for it, including a publicly reported UFC case.

Safety

The honest answer is that long-term human safety is unknown. There are no large or long human safety studies. A recurring theoretical concern is that a compound which promotes blood-vessel growth could, in principle, support tumor growth; there is no human evidence confirming or refuting this. The FDA has flagged immune reactions and impurities, and because the supply is gray-market, products may be mislabeled or contaminated. Anecdotal user reports include itching, anxiety, and low mood, but these are uncontrolled and prove nothing about cause.

Bottom line

BPC-157 has a large, encouraging animal literature and a devoted following, but the human evidence needed to call it safe or effective simply does not exist yet. It is unapproved, its regulatory status is in flux, and it is banned for competitive athletes. Treat the enthusiasm as a hypothesis, not a result. This is not medical advice.

Evidence grade: Animal only.

BPC-157: Big Claims, Almost No Human Evidence